tiprankstipranks
Dianthus Therapeutics (DE:87E)
XETRA:87E
Germany Market
87E
Dianthus Therapeutics
RESEARCH TOOLSreports

Dianthus Therapeutics (87E) Stock Forecast & Price Target

0 Followers
See the Price Targets and Ratings of:

87E Analyst Ratings

Strong Buy
13Ratings
Strong Buy
13 Buy
0 Hold
0 Sell
Based on 13 analysts giving stock ratings to
Dianthus
Therapeutics
in the past 3 months
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers​ in the past 3 months

87E Stock 12 Month Forecast

Average Price Target

€121.48
▲(34.23% Upside)
Based on 13 Wall Street analysts offering 12 month price targets for Dianthus Therapeutics in the last 3 months. The average price target is €121.48 with a high forecast of €172.75 and a low forecast of €105.38. The average price target represents a 34.23% change from the last price of €90.50.
{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"16":"€16","173":"€173","55.25":"€55.3","94.5":"€94.5","133.75":"€133.8"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":172.754088,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">€172.75</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":121.47753369818183,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">€121.48</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":105.37999368,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">€105.38</span>\n  </div></div>","useHTML":true}}],"tickPositions":[16,55.25,94.5,133.75,173],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Nov<br/>2025","6":"Feb<br/>2026","9":"May<br/>2026","12":"Aug<br/>2026","25":"Aug<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,99,104.67339138461539,110.34678276923077,116.02017415384616,121.69356553846154,127.36695692307693,133.0403483076923,138.71373969230768,144.38713107692308,150.06052246153845,155.73391384615385,161.40730523076923,167.08069661538462,{"y":172.754088,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,99,100.7290410537063,102.4580821074126,104.18712316111888,105.91616421482517,107.64520526853147,109.37424632223777,111.10328737594406,112.83232842965036,114.56136948335666,116.29041053706294,118.01945159076924,119.74849264447553,{"y":121.47753369818183,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,99,99.49076874461538,99.98153748923077,100.47230623384615,100.96307497846153,101.45384372307693,101.94461246769231,102.43538121230769,102.92614995692307,103.41691870153846,103.90768744615384,104.39845619076922,104.88922493538462,{"y":105.37999368,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":17.9,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 27,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":19.9,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 37,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":33,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 31,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":29.2,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 26,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":37.4,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 14,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":35,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 15,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":44,"date":1769904000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 13,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":45.4,"date":1772323200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 32,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":72.5,"date":1775001600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 29,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":70.5,"date":1777593600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 33,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":80,"date":1780272000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 25,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":84.5,"date":1782864000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 23,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":99,"date":1785542400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 26,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}
Highest Price Target€172.75Average Price Target€121.48Lowest Price Target€105.38
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts​

Detailed List of Analyst Forecasts​
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
Stifel Nicolaus Analyst forecast on DE:87E
Alex Thompson CFA
Stifel Nicolaus
Stifel Nicolaus
€114.88
Buy
26.94%
Upside
Reiterated
08/13/26
Dianthus Therapeutics (DNTH) Receives a Rating Update from a Top Analyst
Evercore ISI Analyst forecast on DE:87E
Gavin Clark-Gartner
Evercore ISI
Evercore ISI
€115.75
Buy
27.90%
Upside
Reiterated
08/10/26
Analysts' Opinions Are Mixed on These Healthcare Stocks: Hims & Hers Health (NYSE: HIMS) and Dianthus Therapeutics (NASDAQ: DNTH)
H.C. Wainwright Analyst forecast on DE:87E
Swayampakula Ramakanth
H.C. Wainwright
H.C. Wainwright
€112.29→€136.48
Buy
50.80%
Upside
Reiterated
08/06/26
Dianthus price target raised to $158 from $130 at H.C. WainwrightDianthus price target raised to $158 from $130 at H.C. Wainwright
Truist Financial Analyst forecast on DE:87E
Danielle Brill
Truist Financial
Truist Financial
€95.01→€110.56
Buy
22.17%
Upside
Reiterated
08/06/26
Dianthus Therapeutics (DNTH) Gets a Buy from Truist Financial
TD Cowen Analyst forecast on DE:87E
Yaron Werber
TD Cowen
TD Cowen
€129.57
Buy
43.17%
Upside
Assigned
08/05/26
Analysts Conflicted on These Healthcare Names: Dianthus Therapeutics (NASDAQ: DNTH) and American Well (NYSE: AMWL)
Guggenheim Analyst forecast on DE:87E
Yatin Suneja
Guggenheim
Guggenheim
€172.75
Buy
90.89%
Upside
Reiterated
08/05/26
Analysts Are Bullish on These Healthcare Stocks: Dianthus Therapeutics (DNTH), Nyxoah (NYXH)
Wedbush Analyst forecast on DE:87E
Laura Chico
Wedbush
Wedbush
€90.7→€105.38
Buy
16.44%
Upside
Reiterated
08/05/26
Wedbush Reaffirms Their Buy Rating on Dianthus Therapeutics (DNTH)
Clear Street Analyst forecast on DE:87E
William Maughan
Clear Street
Clear Street
€112.29
Buy
24.08%
Upside
Reiterated
08/05/26
Analysts Are Bullish on Top Healthcare Stocks: Alphatec Holdings (ATEC), Tyra Bioscience (TYRA)
Wells Fargo Analyst forecast on DE:87E
Sadia Rahman
Wells Fargo
Wells Fargo
€116.61
Buy
28.85%
Upside
Reiterated
08/05/26
Wells Fargo Sticks to Their Buy Rating for Dianthus Therapeutics (DNTH)
William Blair Analyst forecast on DE:87E
Myles Minter
William Blair
William Blair
―
Buy
―
Reiterated
08/04/26
Analysts Offer Insights on Healthcare Companies: Dianthus Therapeutics (NASDAQ: DNTH) and Viridian Therapeutics (NASDAQ: VRDN)
LifeSci Capital Analyst forecast on DE:87E
Rami Katkhuda
LifeSci Capital
LifeSci Capital
€107.97
Buy
19.31%
Upside
Reiterated
08/04/26
Dianthus Maintained at Buy as Strong Cash Runway and DNTH312 Pipeline Potential Support Unchanged $125 Price Target
Jefferies Analyst forecast on DE:87E
Maury Raycroft
Jefferies
Jefferies
€114.02
Buy
25.99%
Upside
Reiterated
06/15/26
Analysts Offer Insights on Healthcare Companies: Dianthus Therapeutics (NASDAQ: DNTH) and Medpace Holdings (NASDAQ: MEDP)
Raymond James Analyst forecast on DE:87E
Ryan Deschner
Raymond James
Raymond James
―
Buy
―
Reiterated
06/12/26
Wall Street Analysts Are Bullish on Top Healthcare Picks
Wolfe Research Analyst forecast on DE:87E
Andy Chen
Wolfe Research
Wolfe Research
€84.65
Buy
-6.46%
Downside
Reiterated
04/08/26
Bullish View on Dianthus: Claseprubart’s Differentiated Complement Inhibition and Underappreciated Bifunctional Pipeline Drive Buy Rating
Robert W. Baird Analyst forecast on DE:87E
Colleen M. Kusy
Robert W. Baird
Robert W. Baird
€57.87→€114.02
Buy
25.99%
Upside
Reiterated
03/09/26
Dianthus price target raised to $132 from $67 at BairdDianthus price target raised to $132 from $67 at Baird
Analyst Type
Any
Any
Human Analysts
Ranks
Any
Any
Analyst Rating
Any
Any
Upside/ Downside
Any
Any
Action
Any
Any
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
Stifel Nicolaus Analyst forecast on DE:87E
Alex Thompson CFA
Stifel Nicolaus
Stifel Nicolaus
€114.88
Buy
26.94%
Upside
Reiterated
08/13/26
Dianthus Therapeutics (DNTH) Receives a Rating Update from a Top Analyst
Evercore ISI Analyst forecast on DE:87E
Gavin Clark-Gartner
Evercore ISI
Evercore ISI
€115.75
Buy
27.90%
Upside
Reiterated
08/10/26
Analysts' Opinions Are Mixed on These Healthcare Stocks: Hims & Hers Health (NYSE: HIMS) and Dianthus Therapeutics (NASDAQ: DNTH)
H.C. Wainwright Analyst forecast on DE:87E
Swayampakula Ramakanth
H.C. Wainwright
H.C. Wainwright
€112.29→€136.48
Buy
50.80%
Upside
Reiterated
08/06/26
Dianthus price target raised to $158 from $130 at H.C. WainwrightDianthus price target raised to $158 from $130 at H.C. Wainwright
Truist Financial Analyst forecast on DE:87E
Danielle Brill
Truist Financial
Truist Financial
€95.01→€110.56
Buy
22.17%
Upside
Reiterated
08/06/26
Dianthus Therapeutics (DNTH) Gets a Buy from Truist Financial
TD Cowen Analyst forecast on DE:87E
Yaron Werber
TD Cowen
TD Cowen
€129.57
Buy
43.17%
Upside
Assigned
08/05/26
Analysts Conflicted on These Healthcare Names: Dianthus Therapeutics (NASDAQ: DNTH) and American Well (NYSE: AMWL)
Guggenheim Analyst forecast on DE:87E
Yatin Suneja
Guggenheim
Guggenheim
€172.75
Buy
90.89%
Upside
Reiterated
08/05/26
Analysts Are Bullish on These Healthcare Stocks: Dianthus Therapeutics (DNTH), Nyxoah (NYXH)
Wedbush Analyst forecast on DE:87E
Laura Chico
Wedbush
Wedbush
€90.7→€105.38
Buy
16.44%
Upside
Reiterated
08/05/26
Wedbush Reaffirms Their Buy Rating on Dianthus Therapeutics (DNTH)
Clear Street Analyst forecast on DE:87E
William Maughan
Clear Street
Clear Street
€112.29
Buy
24.08%
Upside
Reiterated
08/05/26
Analysts Are Bullish on Top Healthcare Stocks: Alphatec Holdings (ATEC), Tyra Bioscience (TYRA)
Wells Fargo Analyst forecast on DE:87E
Sadia Rahman
Wells Fargo
Wells Fargo
€116.61
Buy
28.85%
Upside
Reiterated
08/05/26
Wells Fargo Sticks to Their Buy Rating for Dianthus Therapeutics (DNTH)
William Blair Analyst forecast on DE:87E
Myles Minter
William Blair
William Blair
―
Buy
―
Reiterated
08/04/26
Analysts Offer Insights on Healthcare Companies: Dianthus Therapeutics (NASDAQ: DNTH) and Viridian Therapeutics (NASDAQ: VRDN)
LifeSci Capital Analyst forecast on DE:87E
Rami Katkhuda
LifeSci Capital
LifeSci Capital
€107.97
Buy
19.31%
Upside
Reiterated
08/04/26
Dianthus Maintained at Buy as Strong Cash Runway and DNTH312 Pipeline Potential Support Unchanged $125 Price Target
Jefferies Analyst forecast on DE:87E
Maury Raycroft
Jefferies
Jefferies
€114.02
Buy
25.99%
Upside
Reiterated
06/15/26
Analysts Offer Insights on Healthcare Companies: Dianthus Therapeutics (NASDAQ: DNTH) and Medpace Holdings (NASDAQ: MEDP)
Raymond James Analyst forecast on DE:87E
Ryan Deschner
Raymond James
Raymond James
―
Buy
―
Reiterated
06/12/26
Wall Street Analysts Are Bullish on Top Healthcare Picks
Wolfe Research Analyst forecast on DE:87E
Andy Chen
Wolfe Research
Wolfe Research
€84.65
Buy
-6.46%
Downside
Reiterated
04/08/26
Bullish View on Dianthus: Claseprubart’s Differentiated Complement Inhibition and Underappreciated Bifunctional Pipeline Drive Buy Rating
Robert W. Baird Analyst forecast on DE:87E
Colleen M. Kusy
Robert W. Baird
Robert W. Baird
€57.87→€114.02
Buy
25.99%
Upside
Reiterated
03/09/26
Dianthus price target raised to $132 from $67 at BairdDianthus price target raised to $132 from $67 at Baird
Stocks with the Highest Top Analyst Consensus in the Healthcare Sector
AVBPArriVent BioPharma, Inc.
BTSGBrightSpring Health Services, Inc.
AMLXAmylyx Pharmaceuticals Inc
IMMXImmix Biopharma
JBIOJade Biosciences
Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Dianthus Therapeutics

3 Months
Gavin Clark-GartnerEvercore ISI
Success Rate
8/8 ratings generated profit
100%
Average Return
+51.13%
Copying Gavin Clark-Gartner's trades and holding each position for 3 Months would result in 100.00% of your transactions generating a profit, with an average return of +51.13% per trade.
1 Year
Gavin Clark-GartnerEvercore ISI
Success Rate
8/8 ratings generated profit
100%
Average Return
+211.72%
Copying Gavin Clark-Gartner's trades and holding each position for 1 Year would result in 100.00% of your transactions generating a profit, with an average return of +211.72% per trade.
2 Years
Yaron WerberTD Cowen
Success Rate
12/12 ratings generated profit
100%
Average Return
+270.20%
Copying Yaron Werber's trades and holding each position for 2 Years would result in 100.00% of your transactions generating a profit, with an average return of +270.20% per trade.
The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

87E Analyst Recommendation Trends

Rating
Apr 26
May 26
Jun 26
Jul 26
Aug 26
Strong Buy
13
13
8
7
7
Buy
16
20
17
16
19
Hold
0
1
1
1
0
Sell
0
0
0
0
0
Strong Sell
0
0
0
0
0
total
29
34
26
24
26
In the current month, 87E has received 26 Buy Ratings, 0 Hold Ratings, and 0 Sell Ratings. 87E average Analyst price target in the past 3 months is 121.48.
Each month's total comprises the sum of three months' worth of ratings.

87E Financial Forecast

87E Earnings Forecast

Next quarter’s earnings estimate for 87E is -€0.86 with a range of -€0.98 to -€0.63. The previous quarter’s EPS was -€0.78. 87E beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 57.80% of the time in the same period. In the last calendar year 87E has Performed in-line its overall industry.
Next quarter’s earnings estimate for 87E is -€0.86 with a range of -€0.98 to -€0.63. The previous quarter’s EPS was -€0.78. 87E beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 57.80% of the time in the same period. In the last calendar year 87E has Performed in-line its overall industry.

87E Sales Forecast

Next quarter’s sales forecast for 87E is €347.55K with a range of €0.00 to €866.70K. The previous quarter’s sales results were €659.56K. 87E beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 50.04% of the time in the same period. In the last calendar year 87E has Performed in-line its overall industry.
Next quarter’s sales forecast for 87E is €347.55K with a range of €0.00 to €866.70K. The previous quarter’s sales results were €659.56K. 87E beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 50.04% of the time in the same period. In the last calendar year 87E has Performed in-line its overall industry.

87E Stock Forecast FAQ

What is DE:87E’s average 12-month price target, according to analysts?
Based on analyst ratings, Dianthus Therapeutics’s 12-month average price target is 121.48.
    What is DE:87E’s upside potential, based on the analysts’ average price target?
    Dianthus Therapeutics has 34.23% upside potential, based on the analysts’ average price target.
      Can I see which stocks the top-ranking analysts are rating?
      Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
        How can I follow the stock ratings of top Wall Street analysts?
        Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
          Is Dianthus Therapeutics a Buy, Sell or Hold?
          Dianthus Therapeutics has a consensus rating of Strong Buy, which is based on 13 buy ratings, 0 hold ratings and 0 sell ratings.
            What is Dianthus Therapeutics’s share price target?
            The average share price target for Dianthus Therapeutics is 121.48. This is based on 13 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
            The highest analyst share price target is €172.75 ,and the lowest forecast is €105.38. The average share price target represents 34.23% Increase from the current price of €90.5.
              What do analysts say about Dianthus Therapeutics?
              Dianthus Therapeutics’s analyst rating consensus is a Strong Buy. This is based on the ratings of 13 Wall Streets Analysts.
                How can I buy shares of Dianthus Therapeutics?
                To buy shares of DE:87E, you can open a brokerage account. See exclusive account opening deals on our Best Online Brokers page.